Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMKZNTY)

Drug Name
A-71623 Drug Info
Synonyms
A-71623; 130408-77-4; CHEMBL323521; A 71623; A71623; (3S)-4-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]-methylamino]-3-[[(2S)-2-[[(2S)-3-(1H-indol-3-yl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]amino]-6-[(2-methylphenyl)carbamoylamino]hexanoyl]amino]-4-oxobutanoic acid; PDSP1_000879; AC1L3TQM; GTPL858; CHEMBL337366; ZINC95610808; PDSP2_000865; BDBM50003666; Boc-trp-lys(epsilon-N-2-methylphenylaminocarbonyl)-asp-(N-methyl)-phe-NH2; AKOS024457082; KB-270509; B7046; J-005804
Indication
Disease Entry ICD 11 Status REF
Obesity 5B81 Terminated [1]
Cross-matching ID
PubChem CID
121964
CAS Number
CAS 130408-77-4
TTD Drug ID
DMKZNTY

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Cholecystokinin receptor type A (CCKAR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dexloxiglumide DM52HUD Pancreatic malfunction DC30-DC3Z Phase 2 [3]
proglumide DM4MF9V Influenza virus infection 1E30-1E32 Phase 2 [4]
Lintitript DMS5X94 Obesity 5B81 Discontinued in Phase 2 [5]
Tarazepide DMX6ZYE Gastrointestinal disease DE2Z Discontinued in Phase 2 [6]
GI 181771 DMIUFS4 Obesity 5B81 Discontinued in Phase 2 [7]
Pranazepide DMP43IR Pancreatic malfunction DC30-DC3Z Discontinued in Phase 2 [8]
CE-326597 DMXO49B Obesity 5B81 Discontinued in Phase 2 [9]
UCL-2000; butabindide DML51D0 Obesity 5B81 Discontinued in Phase 1 [10]
SSR-125180 DMSOBW2 Obesity 5B81 Discontinued in Phase 1 [11]
T-0632 DML4M5K Pancreatic malfunction DC30-DC3Z Discontinued in Phase 1 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cholecystokinin receptor type A (CCKAR) TTCG0AL CCKAR_HUMAN Modulator [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 858).
2 Characterization of two novel cholecystokinin tetrapeptide (30-33) analogues, A-71623 and A-70874, that exhibit high potency and selectivity for cholecystokinin-A receptors. Mol Pharmacol. 1991 Mar;39(3):346-51.
3 Full agonists of CCK8 containing a nonhydrolyzable sulfated tyrosine residue. J Med Chem. 1989 Feb;32(2):445-9.
4 Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists. Arzneimittelforschung. 1987 Nov;37(11):1265-8.
5 A cholecystokinin-1 receptor agonist (CCK-8) mediates increased permeability of brain barriers to leptin. Br J Pharmacol. 2008 Jul;154(5):1009-15.
6 Melatonin as modulator of pancreatic enzyme secretion and pancreatoprotector. J Physiol Pharmacol. 2007 Dec;58 Suppl 6:65-80.
7 Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Jul-Aug;25(6):483-506.
8 Dual CCK-A and -B receptor antagonists (I) C9-methyl-1,4-benzodiazepines, Bioorg. Med. Chem. Lett. 7(2):169-174 (1997).
9 Obesity Pharmacotherapy: Current Perspectives and Future Directions. Curr Cardiol Rev. 2013 February; 9(1): 33-54.
10 Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
11 US patent application no. 8,748,419, Antagonists.
12 Effect of T-0632, a cholecystokininA receptor antagonist, on experimental acute pancreatitis. Jpn J Pharmacol. 1997 Feb;73(2):105-12.